http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q#Head http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q#assertion http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q#provenance http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q#pubinfo http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q#assertion http://purl.obolibrary.org/obo/DOID_1558 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_1558 http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB14213 http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q#association http://www.w3.org/2000/01/rdf-schema#label "Perindopril erbumine tablets are contraindicated in patients known to be hypersensitive (including angioedema) to this product or to any other ACE inhibitor. Perindopril erbumine tablets are also contraindicated in patients with hereditary or idiopathic angioedema. [see Drug Interactions (7.8) ] [see Warnings and Precautions (5.1) Angioedema related to previous treatment with an ACE inhibitor, or a history of hereditary or idiopathic angioedema. ( 4 5.1 Do not co-administer aliskiren with perindopril erbumine tablets in patients with diabetes ( 4 7.8 Do not take a neprilysin inhibitor with perindopril erbumine tablets ( 4 Do not administer perindopril erbumine tablets within 36 hours of switching to or from sacubitril/valsartan ( 4" http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q#association https://w3id.org/biolink/vocab/relation https://schema.org/MedicalContraindication https://identifiers.org/drugbank:DB14213 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q#provenance http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q#pubinfo http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q#sig http://purl.org/nanopub/x/hasSignature SQlyhJ8miHaMfcgbRB6fYUABwZ0xjJ0pgQYCZacIZlZeIZIPzRX6dkjktoxJrVPuBCEPuHoxg8Qo4wntZ/lS8TgPnmJ76Z/jFCRwWM+oRL2f49tE4SjZ59xk4cT45kfsnI2pjw50r0TkmMebZJ/kjWSJlSTGUy4gnGr59YDLDH0= http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q http://purl.org/dc/terms/created 2021-08-25T13:42:34.473+02:00 http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY